Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.60 |
| ▸ | TSHR | P16473 | 4/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.42 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | GRIN2D | O15399 | 3/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 3/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.38 |
| ▸ | GRIN2C | Q14957 | 3/20 | 0.38 |
| ▸ | GRIN3A | Q8TCU5 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5872583 | 0.89 | ALDH1A1 (0.72) | ALDH1A1TSHRHIF1AVCAM1TDP1 | |
| SCHEMBL16319820 | 0.86 | ALDH1A1 (0.50) | ALDH1A1TSHRHIF1AVCAM1TDP1 | |
| SCHEMBL31321220 | 0.81 | VCAM1 (0.47) | ALDH1A1TSHRHIF1AVCAM1TDP1 | |
| SCHEMBL18894107 | 0.81 | VCAM1 (0.47) | ALDH1A1TSHRHIF1AVCAM1TDP1 | |
| SCHEMBL104470 | 0.80 | TDP1 (0.52) | ALDH1A1TSHRHIF1AVCAM1TDP1 | |
| SCHEMBL2548910 | 0.78 | CYP19A1 (0.50) | ALDH1A1TSHRHIF1AVCAM1TDP1 | |
| SCHEMBL30391374 | 0.77 | ALDH1A1 (0.42) | ALDH1A1TSHRMAPK1MAPTHTT | |
| SCHEMBL9771595 | 0.76 | ALDH1A1 (0.60) | ALDH1A1TSHRTDP1MAPK1MAPT | |
| SCHEMBL7531924 | 0.76 | TSHR (0.60) | ALDH1A1TSHRHIF1AVCAM1TDP1 | |
| SCHEMBL1358844 | 0.76 | TDP1 (0.39) | ALDH1A1TSHRHIF1AVCAM1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4667460-A1 | MIR-124 INDUCER, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Nanjing Synnocare Pharmaceutical Technology Co., Ltd. (CN) | 2025-12-24 | — | — | EP | disclosed |
| US-20250333429-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | FORWARD THERAPEUTICS INC (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250333399-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | KHORA SPV 1 LLC (US) | 2025-10-30 | — | — | US | disclosed |
| EP-4622981-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | Forward Therapeutics, Inc. (US) | 2025-10-01 | — | — | EP | disclosed |
| US-12384808-B2 | Modulators of TNF-α activity | FORWARD THERAPEUTICS, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| US-12331039-B2 | Inhibitors of fibroblast growth factor receptor kinases | KHORA SPV 1, LLC (US) | 2025-06-17 | — | — | US | disclosed |
| WO-2025037871-A1 | TRICYCLIC COMPOUND AND USE THEREOF AS MAT2A INHIBITOR | 에스케이바이오팜 주식회사 | 2025-02-20 | — | — | WO | disclosed |
| CN-115135636-B | Quinoxalinone derivatives as irreversible inhibitors of KRAS G12C muteins | 北京泰德制药股份有限公司 | 2024-08-23 | — | — | CN | disclosed |
| WO-2024169848-A1 | MIR-124 INDUCER, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 南京同诺康医药科技有限公司 | 2024-08-22 | — | — | WO | disclosed |
| US-20240247014-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | FORWARD THERAPEUTICS, INC. | 2024-07-25 | — | — | US | disclosed |
| WO-2024112796-A1 | MODULATORS OF TNF-α ACTIVITY | FORWARD THERAPEUTICS, INC. (US) | 2024-05-30 | — | — | WO | disclosed |
| US-20230374015-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | KINNATE BIOPHARMA INC. | 2023-11-23 | — | — | US | disclosed |
| CN-115151532-B | Quinoxalindione derivatives as irreversible inhibitors of KRAS G12C muteins | 北京泰德制药股份有限公司 | 2023-06-06 | — | — | CN | disclosed |
| CN-116057045-A | Fibroblast growth factor receptor kinase inhibitors | 金耐特生物制药公司 | 2023-05-02 | — | — | CN | disclosed |
| EP-4161656-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | Kinnate Biopharma Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| US-20230078839-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | KHORA SPV 1, LLC | 2023-03-16 | — | — | US | disclosed |
| CN-115151532-A | Quinoxalinedione derivatives as irreversible inhibitors of KRAS G12C muteins | 北京泰德制药股份有限公司 | 2022-10-04 | — | — | CN | disclosed |
| CN-115135636-A | Quinoxalinone derivatives as irreversible inhibitors of KRAS G12C mutant proteins | 北京泰德制药股份有限公司 | 2022-09-30 | — | — | CN | disclosed |
| US-11345681-B1 | Inhibitors of fibroblast growth factor receptor kinases | KINNATE BIOPHARMA INC. (US) | 2022-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374015-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | FGFR1, FGFR2, FGFR3 | ALDH1A1 2169/4885TSHR 1346/4885HIF1A 1230/4885 |
| US-12331039-B2 | Inhibitors of fibroblast growth factor receptor kinases | FGFR1, FGFR2, FGFR3 | ALDH1A1 2169/4885TSHR 1346/4885HIF1A 1230/4885 |
| US-20250333399-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | FGFR1, FGFR2, FGFR3 | ALDH1A1 2169/4885TSHR 1346/4885HIF1A 1230/4885 |
| US-12384808-B2 | Modulators of TNF-α activity | TNF, NFKBIA, TNFRSF1A | ALDH1A1 2291/4885TSHR 3067/4885HIF1A 1333/4885 |
| US-20250333429-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | TNF, NFKBIA, TNFRSF1A | ALDH1A1 2563/4885TSHR 2908/4885HIF1A 1682/4885 |
| US-11345681-B1 | Inhibitors of fibroblast growth factor receptor kinases | FGFR1, FGFR2, FGFR3 | ALDH1A1 2169/4885TSHR 1346/4885HIF1A 1230/4885 |
| US-20240247014-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | TNF, NFKBIA, TNFRSF1A | ALDH1A1 2563/4885TSHR 2908/4885HIF1A 1682/4885 |
| US-20230078839-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | FGFR1, FGFR2, FGFR3 | ALDH1A1 2169/4885TSHR 1346/4885HIF1A 1230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.